You are here: Industry Insights > Janssen

News List

Janssen COVID-19 Vaccine – one regulator blocks use, another promotes it europeanpharmaceuticalreview
June 16, 2021
EU recommends that batches of Janssen COVID-19 Vaccine not be released for use due to a cross contamination report, while the FDA authorises use of drug substance from the facility where the contamination occurred.
FDA Takes Steps to Increase Availability of the Janssen COVID-19 Vaccine americanpharmaceuticalreview
June 16, 2021
Following careful review and deliberation, the U.S. FDA is taking important steps that will allow a critically needed supply of the Janssen (Johnson & Johnson) COVID-19 Vaccine to be made available.
Janssen COVID-19 Vaccine Shipment Made with Drug Substance from Emergent BioSolutions Fails QA americanpharmaceuticalreview
June 16, 2021
Health Canada has completed its quality review of the shipment of Janssen vaccines that are currently in quarantine. To protect the health and safety of Canadians in response to concerns regarding a drug substance produced at the Emergent BioSolutions ...
Janssen COVID-19 Vaccine can protect against variants of concern europeanpharmaceuticalreview
June 11, 2021
Trial shows the single-shot Janssen COVID-19 Vaccine generates robust immune responses against several COVID-19 variants.
Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab americanpharmaceuticalreview
June 09, 2021
Cilag GmbH International, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced its decision to discontinue the collaboration and license agreement with argenx for cusatuzumab, an investigational therapeutic antibody that targets ...
Tremfya® improves psoriatic arthritis joint function and skin clearance europeanpharmaceuticalreview
June 08, 2021
Over 50 percent of psoriatic arthritis patients treated with Tremfya® (guselkumab) achieved ≥20 percent improvement in joint symptoms and complete skin clearance at one year.
UK approves Janssen COVID-19 Vaccine europeanpharmaceuticalreview
June 03, 2021
The Janssen COVID-19 Vaccine has been granted conditional marketing authorisation for use in people aged 18 and over in the UK.
Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’ pharmatimes
June 03, 2021
Janssen has reported new data for its B-cell maturation antigen (BCMA) directed CAR T therapy ciltacabtagene autoleucel (cilta-cel) in heavily pretreated relapsed/refractory multiple myeloma (RRMM) patients.
NICE green lights Tremfya to treat active psoriatic arthritis pharmatimes
June 01, 2021
Janssen’s IL-23 inhibitor Tremfya has been accepted for NHS use by the UK’s National Institute for Health and Care Excellence (NICE) for the treatment of active psoriatic arthritis (PsA).
Erleada® improves survival without damaging quality of life in prostate cancer trial europeanpharmaceuticalreview
May 31, 2021
Data shows metastatic castration-sensitive prostate cancer patients treated with Erleada® (apalutamide) were 35 percent less likely to die and had maintained quality of life.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page